Monocyte chemoattractant protein-1 in patients with peripheral arterial disease

Mediators of Inflammation

Volumn 13, Issue 1, 2004, Pages 39-43

  Petrkova, Jana ^a   Szotkowska, Jaroslava ^a   Hermanova, Zuzana ^a   Lukl, Jan ^a   Petrek, Martin ^a  

^a PALACKÝ UNIVERSITY   (Czech Republic)

Author keywords

Artheritis obliterans; Atherosclerosis; CC chemokine ligand 2; Low density lipoprotein; Monocyte chemoattractant protein 1; Risk factors

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; TRIACYLGLYCEROL;

ADULT; ARTERY DISEASE; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETES MELLITUS; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HYPERTENSION; LIPOPROTEIN BLOOD LEVEL; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RANK SUM TEST; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; ARTERIES; ARTERIOSCLEROSIS; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHEMOKINE CCL2; DIABETES COMPLICATIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; HYPERTENSION; IMMUNOASSAY; LIPIDS; MALE; MIDDLE AGED; PERIPHERAL VASCULAR DISEASES; PILOT PROJECTS; RISK FACTORS; SMOKING;

EID: 2442565746     PISSN: 09629351     EISSN: None     Source Type: Journal    
DOI: 10.1080/09629350410001664752     Document Type: Article

References (24)

1. Mackay CR. Chemokines: immunology's high impact factors. Nat Immunol 2001; 2: 95-101.
2. Gerald C, Rollins BJ. Chemokines and disease. Nat Immunol 2001; 2: 108-115.
3. Vaddi K. Monocyte chemoattractant protein-1. In: Vaddi K, Keller M, Newton RC, eds. The Chemokine Fact Book, 1st edn, San Diego, CA: Academic Press, 1997: 86-98.
4. Valente AJ, Rozek MM, Sprague EA, Schwartz CJ. Mechanisms in intimal monocyte-macrophage recruitment. A special role for monocyte chemotactic protein-1. Circulation 1992; 86 (6 Suppl): III20-III25.
5. Matsumori A, Furukawa Y, Hashimoto T, et al. Plasma levels of the monocyte chemotactic and activating factor/monocyte chemoattractant protein-1 are elevated in patients with acute myocardial infarction. J Mol Cell Cardiol 1997; 29: 419-423.
6. Parissis JT, Venetsanou KF, Kalantzi MV, Mentzikof DG, Ziras NG, Karas SM. Macrophage chemoattractant protein and macrophage inflammatory protein-1alpha serum profiles in hypertensive patients with or without significant hyperlipidemia. Eur J Internal Med 2000; 11: 27-32.
7. Bierman EL. Atherosclerosis and other forms of arteriosclerosis. In: Wilson JD, Braunwald E, Isselbacher KJ, et al, eds. Harrison's Principles of Internal Medicine, 12th edn, New York: McGraw-Hill, 1991: 992-1001.
8. Ouriel K. Peripheral arterial disease. Lancet 2001; 358: 1257-1264.
9. Ramirez-Tortosa MC, Urbano G, Lopez-Jurado M, et al. Lifestyle changes in free-living patients with peripheral vascular disease (Fontaine stage II) related to plasma and LDL lipid composition: a 15 month follow-up study. Clin Nutr 1999; 18: 281-289.
10. Aukrust P, Ueland T, Muller F, et al. Elevated circulating levels of C-C chemokines in patients with congestive heart failure. Circulation 1998; 97: 1136-1143.
11. Damas JK, Eiken HG, Oie E, et al. Myocardial expression of CC- and CXC-chemokines and their receptors in human end-stage heart failure. Cardiovasc Res 2000; 47: 778-787.
12. Gullestad L, Simonsen S, Ueland T, et al. Possible role of proinflammatory cytokines in heart allograft coronary artery disease. Am J Cardiol 1999; 84: 999-1003.
13. Aukrust P, Damas JK, Gullestad L, Froland SS. Chemokines in myocardial failure - pathogenic importance and potential therapeutic targets. Clin Exp Immunol 2001; 124: 343-345.
14. Fuse K, Kodama M, Hanawa H, et al. Enhanced expression and production of monocyte chemoattractant protein-1 in myocarditis. Clin Bxp Immunol 2001; 124: 346-352.
15. Matsui K, Ikeda U, Murakami Y, Yoshioka T, Shimada K. Intravenous prostaglandin E1 reduces monocyte chemoattractant protein-1 levels in peripheral arterial obstructive disease. Am Heart J 2003; 145: 330-333.
16. Davies MJ. The birth, growth, and consequences of the atherosclerotic plaque. Dialogues Cardiovasc Med 1999; 4: 115-130.
17. Maeno Y, Kashiwagi A, Nishio Y, Takahara N, Kikkawa R. IDL can stimulate atherogenic gene expression in cultured human vascular endothelial cells. Diabetes Res Clin Pract 2000; 48: 127-138.
18. Dwivedi A, Anggard EE, Carrier MJ. Oxidized LDL-mediated monocyte adhesion to endothelial cells does not involve NFkappaB. Biochem Biophys Res Commun 2001; 284: 239-244.
19. Brevetti G, Piscione F, Silvestro A, et al. Increased inflammatory status and higher prevalence of three-vessel coronary artery disease in patients with concomitant coronary and peripheral atherosclerosis. Thromb Haemost 2003; 89: 1058-1063.
20. Jilma-Stohlawetz P, Homoncik M, Drucker C, et al. Fy phenotype and gender determine plasma levels of monocyte chemotactic protein. Transfusion 2001; 41: 378-381.
21. Barretto S, Ballman KV, Rooke TW, Kullo IJ. Early-onset peripheral arterial occlusive disease: clinical features and determinants of disease severity and location. Vasc Med 2003; 8: 95-100.
22. Meijer WT, Hoes AW, Rutgers D, Bots ML, Hofman A, Grobbee DE. Peripheral arterial disease in the elderly: the Rotterdam Study. Arterioscler Tromb Vasc Biol 1998; 18: 185-192.
23. McDermott MM, Green D, Greenland P, et al. Relation of levels of hemostatic factors and inflammatory markers to the ankle brachial index. Am J Cardiol 2003; 15: 194-199.
24. Call DR, Nemzek JA, Ebong SJ, et al. Ratio of local to systemic chemokine concentrations regulates neutrophil recruitment. Am J Pathol 2001; 158: 715-721.